Evolving Immunotherapy in Myeloma: Insights on Bispecific and Trispecific Antibodies from ASCO 2025

home / post-conference-perspectives / evolving-immunotherapy-in-myeloma-insights-on-bispecific-and-trispecific-antibodies-from-asco

A panelist discusses the most significant research findings on bispecific antibody therapy for relapsed/refractory multiple myeloma presented at ASCO 2025, highlighting breakthroughs and novel therapies that may shift treatment paradigms, assessing the clinical implications for improving patient management and outcomes, and exploring emerging trispecific therapies with potential to further transform future care.

Episodes

AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo